HomeCompareCFRLF vs ABBV

CFRLF vs ABBV: Dividend Comparison 2026

CFRLF yields 5.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CFRLF wins by $847.7K in total portfolio value
10 years
CFRLF
CFRLF
● Live price
5.97%
Share price
$0.64
Annual div
$0.04
5Y div CAGR
48.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$950.0K
Annual income
$576,136.88
Full CFRLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CFRLF vs ABBV

📍 CFRLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFRLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFRLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFRLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFRLF
Annual income on $10K today (after 15% tax)
$507.54/yr
After 10yr DRIP, annual income (after tax)
$489,716.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CFRLF beats the other by $468,660.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFRLF + ABBV for your $10,000?

CFRLF: 50%ABBV: 50%
100% ABBV50/50100% CFRLF
Portfolio after 10yr
$526.2K
Annual income
$300,454.32/yr
Blended yield
57.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CFRLF
No analyst data
Altman Z
0.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFRLF buys
0
ABBV buys
0
No recent congressional trades found for CFRLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFRLFABBV
Forward yield5.97%3.06%
Annual dividend / share$0.04$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.1%40.6%
Portfolio after 10y$950.0K$102.3K
Annual income after 10y$576,136.88$24,771.77
Total dividends collected$888.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CFRLF vs ABBV ($10,000, DRIP)

YearCFRLF PortfolioCFRLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,584$884.31$11,550$430.00+$34.00CFRLF
2$13,813$1,417.91$13,472$627.96+$341.00CFRLF
3$17,120$2,340.13$15,906$926.08+$1.2KCFRLF
4$22,333$4,014.47$19,071$1,382.55+$3.3KCFRLF
5$31,145$7,248.36$23,302$2,095.81+$7.8KCFRLF
6$47,316$13,990.95$29,150$3,237.93+$18.2KCFRLF
7$80,048$29,419.84$37,536$5,121.41+$42.5KCFRLF
8$154,541$68,889.72$50,079$8,338.38+$104.5KCFRLF
9$349,444$184,085.56$69,753$14,065.80+$279.7KCFRLF
10$950,042$576,136.88$102,337$24,771.77+$847.7KCFRLF

CFRLF vs ABBV: Complete Analysis 2026

CFRLFStock

China Aircraft Leasing Group Holdings Limited, an investment holding company, provides aircraft leasing services to airline companies in Mainland China and internationally. It is involved in the aircraft leasing, and purchase and leaseback; portfolio trading and asset management; fleet upgrade; aircraft disassembly; and component sales activities, as well as in the aircraft maintenance, repair, and overhaul activities. The company also offers financing and management services. As of December 31, 2021, it had a fleet of 127 owned and 25 managed aircraft. The company was formerly known as China Aircraft Leasing Company Limited and changed its name to China Aircraft Leasing Group Holdings Limited in September 2013. China Aircraft Leasing Group Holdings Limited was founded in 2006 and is headquartered in Admiralty, Hong Kong.

Full CFRLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CFRLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFRLF vs SCHDCFRLF vs JEPICFRLF vs OCFRLF vs KOCFRLF vs MAINCFRLF vs JNJCFRLF vs MRKCFRLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.